Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bcp.2020.114057 http://scihub22266oqcxt.onion/10.1016/j.bcp.2020.114057 32470547!7250789!32470547     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biochem+Pharmacol 2020 ; 178 (ä): 114057 Nephropedia Template TP {{tp|p=32470547|t=2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost |pdf=|usr=}}{{32470547}} gab.com Text Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost JO: Biochem Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32470547 #FOAvip COVID-19 is an ongoing viral pandemic disease that is caused by SARS-CoV2, inducing severe pneumonia in humans. However, several classes of repurposed drugs have been recommended, no specific vaccines or effective therapeutic interventions for COVID-19 are developed till now. Viral dependence on ACE-2, as entry receptors, drove the researchers into RAS impact on COVID-19 pathogenesis. Several evidences have pointed at Neprilysin (NEP) as one of pulmonary RAS components. Considering the protective effect of NEP against pulmonary inflammatory reactions and fibrosis, it is suggested to direct the future efforts towards its potential role in COVID-19 pathophysiology. Thus, the review aimed to shed light on the potential beneficial effects of NEP pathways as a novel target for COVID-19 therapy by summarizing its possible molecular mechanisms. Additional experimental and clinical studies explaining more the relationships between NEP and COVID-19 will greatly benefit in designing the future treatment approaches. Twit Text FOAVip Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost ????Biochem Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32470547 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32470547 #FOAvip English Wikipedia <ref>{{Cite pmid|32470547}}</ref> Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost #MMPMID32470547 Mohammed El Tabaa M; Mohammed El Tabaa M Biochem Pharmacol 2020[Aug]; 178 (ä): 114057 PMID32470547show ga COVID-19 is an ongoing viral pandemic disease that is caused by SARS-CoV2, inducing severe pneumonia in humans. However, several classes of repurposed drugs have been recommended, no specific vaccines or effective therapeutic interventions for COVID-19 are developed till now. Viral dependence on ACE-2, as entry receptors, drove the researchers into RAS impact on COVID-19 pathogenesis. Several evidences have pointed at Neprilysin (NEP) as one of pulmonary RAS components. Considering the protective effect of NEP against pulmonary inflammatory reactions and fibrosis, it is suggested to direct the future efforts towards its potential role in COVID-19 pathophysiology. Thus, the review aimed to shed light on the potential beneficial effects of NEP pathways as a novel target for COVID-19 therapy by summarizing its possible molecular mechanisms. Additional experimental and clinical studies explaining more the relationships between NEP and COVID-19 will greatly benefit in designing the future treatment approaches. |Angiotensin I/pharmacology/therapeutic use[MESH] |Angiotensin Receptor Antagonists/pharmacology/therapeutic use[MESH] |Angiotensin-Converting Enzyme Inhibitors/pharmacology/therapeutic use[MESH] |Antiviral Agents/pharmacology/*therapeutic use[MESH] |Betacoronavirus/*drug effects/physiology[MESH] |COVID-19[MESH] |Coronavirus Infections/physiopathology/*prevention & control/virology[MESH] |Drug Repositioning/*methods/statistics & numerical data/trends[MESH] |Humans[MESH] |Neprilysin/*antagonists & inhibitors/metabolism[MESH] |Pandemics/*prevention & control[MESH] |Peptide Fragments/pharmacology/therapeutic use[MESH] |Pneumonia, Viral/physiopathology/*prevention & control/virology[MESH] |SARS-CoV-2[MESH]Targeting Neprilysin (NEP) pathways: A potential new hope to defeat CO(epmc).pdf DeepDyve Pubget Overpricing